A major obstacle in the treatment of acute myeloid leukemia (AML) is refractory disease or
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …

Recent studies have uncovered various physiological functions of CDK5 in many
nonneuronal tissues. Upregulation of CDK5 and/or its activator p35 in neurons promotes …

The internal tandem duplication of the FMS-like tyrosine kinase 3 (FLT3-ITD) is one of the
most frequent genetic alterations in acute myeloid leukemia (AML). Limited and transient …

Inhibitors of dihydroorotate dehydrogenase (DHODH), a key enzyme for de novo synthesis
of pyrimidine nucleotides, have failed in clinical trials for various cancers despite robust …

Monocytic acute myeloid leukemia (AML) responds poorly to current treatments, including
venetoclax-based therapy. We conducted in vivo and in vitro CRISPR-Cas9 library …

Patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) have a poor
prognosis with few therapeutic options. With the goal of identifying novel therapeutic targets …

Simple Summary The treatment and cure of FLT3-mutated AML (FLT3mut) is still a
challenge despite the availability of mutation-targeted FLT3 inhibitors (FLT3i). This is a …

One of the distinguishing properties of hematopoietic stem cells is their ability to self-renew.
Since self-renewal is important for the continuous replenishment of the hematopoietic stem …

We review the importance of monocytic differentiation and differentiation induction in non-
APL (acute promyelocytic leukemia) variants of acute myeloid leukemia (AML), a …

Acute Myeloid Leukemia is one of the most aggressive blood cancers with a high frequency
of relapse. While standard chemotherapy is able to target rapidly proliferating immature …